(WO2019/129728) Claims 1. A composition comprising LC-PUFAs and an iron source, characterized in that the iron source is ferrous sulphate monohydrate. 2. A composition according to claim 1 , characterized in that the composition is a nutritional composition. 3. A composition according to any one of the preceding claims, characterized in that the iron source is present in an amount such as to provide 6 to 50 mg of iron per 10Og of composition. 4. A composition according to any one of the preceding claims, characterized in that the composition comprises 10 to 1000 mg of LC-PUFAs per 100 g, based on the total dry weight of the composition. 5. A composition according to claim 4, characterized in that the composition comprises 10 to 750 mg of LC-PUFAs per 100 g, based on the total dry weight of the composition. 6. A composition according to claim 5, characterized in that the composition comprises 10 to 500 mg of LC-PUFAs per 100 g, based on the total dry weight of the composition. 7. An iron source for use in the fortification of a composition comprising LC-PUFAs, characterized in that the iron source is ferrous sulphate monohydrate. 8. An edible composition comprising LC-PUFAs and an added iron source, for use in a method of preventing, reducing and/or treating iron deficiency in an individual, characterized in that the added iron source is ferrous sulphate monohydrate. 9. A composition according to any one of claims 1 to 6, for use in a method of providing a nutrition to an individual comprising feeding the individual with the composition, wherein the composition is an edible composition. 10. A method for reducing and/or preventing the oxidation of LC-PUFAs in a composition comprising an added iron source, characterized in that the iron source if ferrous sulphate monohydrate. 1 1. A method according to claim 10, characterized in that ferrous sulphate monohydrate reduces and/or prevents the oxidation of the LC-PUFAs. 12. A composition according to any one of claims 1 to 6, for use in the prevention, amelioration or treatment of malnutrition, metabolic diseases, neuro- degenerative diseases. 13. A composition according to any one of claims 1 to 6, for use in the promotion of the development of the nervous system and/or of the retina, in the promotion and/or improvement of the mental performance, behavioural and visual functions of an infant or a child, for strengthening immunity, including the development of gut microflora, and/or for reducing the risk of the development of overweight, obesity and insulin resistance.
最新评论
暂无评论。